Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$34.71M$34.71M−10.8% vs Q1 2025 Net Income-$8.11M-$8.11MN/M vs Q1 2025 EPS Diluted-$0.04-$0.04N/M vs Q1 2025 Gross Profit$24,073,000−20.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$1,540,000N/M Free Cash Flowderived-$1,931,000N/M Margins · derivedGross margin69.4%−8.9 pt vs Q1 2025
Operating margin-13.7%−21.8 pt vs Q1 2025
Net margin-23.4%−30.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 11, 2026 · 41 d after period end